Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cIPV + bOPV (Candy)
- Development stage
- Phase 4
- Lead developer
- Institute of Medical Biology Chinese Academy of Medical Sciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
cIPV + bOPV (Candy) is a sequential immunization regimen for the prevention of poliomyelitis, developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS). The regimen combines a conventional inactivated poliovirus vaccine (cIPV), which contains inactivated Salk strains of poliovirus types 1, 2, and 3, with a bivalent oral poliovirus vaccine (bOPV) containing live-attenuated Sabin strains of types 1 and 3. The bOPV component is uniquely formulated as a dragee, often referred to as a candy formulation. This approach is part of the global strategy to eradicate polio by providing mucosal immunity through OPV while ensuring protection against type 2 poliovirus and reducing the risk of vaccine-associated paralytic polio (VAPP) through the inclusion of IPV. The regimen is typically evaluated in infants to determine the optimal sequence and number of doses for robust systemic and mucosal protection.
- Other names
- 1-dose cIPV + 2-doses bOPV (Candy)2-doses cIPV + 1-dose bOPV (Candy)cIPV + bOPV dragee
02
Targets
CD4+ T-cell receptor recognizing poliovirus capsid-derived peptidesPV-TCR (Poliovirus capsid-specific CD8+ T-cell receptor)PRR (Pattern recognition receptors)PV-D-BCR (Naïve B-cell receptor specific for poliovirus D-antigen)
Beyond the preview
Go deeper on cIPV + bOPV (Candy).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cIPV + bOPV (Candy).